Latest advancements
The Cure SMA drug pipeline is one of the primary ways we evaluate the success of our research program. The pipeline identifies the major drug programs in development, and tracks…
Community update January 4, 2018
Dear Canadian SMA Community and its supporters, Before the Christmas holidays, our community received a shocking response from CDEC (Canadian Drug Expert Committee) of only recommending reimbursement of a small…
Biogen Community Update – December 22, 2017
Biogen Community Update – December 22, 2017 Dear members of the SMA community, In response to your request for information, we would like to provide you with an update on…
BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA)
BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA) Ottawa – December 22,…
NOT recommending the listing of Spinraza for any type of SMA in Quebec
Dear SMA Community, We have had a response today from INESS which is the Insitut national d’excellence en sant’ et en services sociaux. They have stated that they are NOT…
2017 Canadian sponsors
Sponsor announcement
Cure SMA Canada Conference – Registration still available!!
Hyatt Regency – King St. W, Toronto, Ontario November 5, 2017 Held in conjunction with the CORD (Canadian Organization for Rare Diseases) conference which will be November 6-7, 2017 at…
next steps following Health Canada’s approval of SPINRAZA™ (nusinersen).
Dear members of the SMA community, In response to your request for information, we would like to provide you with an update on Biogen’s SMA360 Canada Patient Support Program and…
update to approuval process
Dear SMA Community, We hope you are enjoying your summer. We know many of you are anxious about the approval process for Spinraza in Canada and therefore would like to…